胆固醇和固酶-5抑制剂在糖尿病膀功能障碍中的简要概述
Georgios Kallinikas1, Georgios Haronis1, Eirini Kallinika2
1Department of Urology, Konstantopouleion-Patision Hospital, N. Ionia, 14233 Attika, Greece.
International journal of molecular sciences
|October 16, 2024
概括
糖尿病膀功能障碍 (DBD) 在糖尿病患者中引起尿道问题. 抗胆固醇药物很常见,但化酶5 (PDE5) 抑制剂在治疗DBD症状方面表现有前途.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖尿病膀功能障碍 (DBD) 在糖尿病患者中呈现出各种下游尿路症状.
- 常见的症状包括尿动频率,急性,尿不和膀不完全排空.
- 抗胆固醇药物经常被处方用于缓解症状.
研究的目的:
- 审查糖尿病膀功能障碍的病理生理学.
- 专注于胆固醇和固酶抑制剂作为DBD的治疗选择.
- 确定DBD治疗的研究缺口和未来方向.
主要方法:
- 这项研究是对现有文献的叙述性审查.
- 它检查了DBD的病理生理学.
- 它分析了抗胆固醇和化酶5 (PDE5) 抑制剂在DBD管理中的作用.
主要成果:
- 有证据表明,糖尿病患者可能受益于PDE5抑制剂.
- 抗胆固醇药物是已知的治疗方法,但PDE5抑制剂提供了潜在的替代或辅助疗法.
- 文献强调了理解DBD机制的差距.
结论:
- 需要进一步的研究才能充分理解DBD机制.
- 新的研究工具和模型,特别是动物模型,对于阐明治疗机制至关重要.
- PDE5抑制剂是未来DBD治疗策略的一个有希望的领域.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
130
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
130
Direct-Acting Cholinergic Agonists: Pharmacokinetics
1.1K
Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
1.1K
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
628
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
628
Direct-Acting Cholinergic Agonists: Therapeutic Uses
698
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
698
Direct-Acting Cholinergic Agonists: Pharmacological Actions
1.2K
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
1.2K
Indirect-Acting Cholinergic Agonists: Mechanism of Action
1.8K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
1.8K


